ArticleStem cells international2026
Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Attenuate IMQ-Induced Psoriasiform Dermatitis: A Preclinical Experimental Study of Exosomal miR-125b-5p/STAT3 Signaling.
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Psoriasis is a chronic inflammatory skin disease driven largely by dysregulation of the IL-23/Th17 axis and excessive keratinocyte proliferation. Human umbilical cord mesenchymal stem cell (MSC)-derived exosomes (hucMSC-Exos) represent a potential cell-free therapeutic strategy, but their mechanisms remain incompletely defined. This study evaluated the effects of hucMSC-Exos in psoriasiform inflammation and investigated the contribution of exosomal miR-125b-5p and its relationship with STAT3 signaling. Methods: hucMSC-Exos were isolated by differential ultracentrifugation and characterized by nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and immunoblotting. Therapeutic effects were assessed in an imiquimod (IMQ)-induced mouse model of psoriasiform dermatitis using PASI-like scoring, histopathology, immunohistochemistry, flow cytometry, and western blotting. Exosomal microRNAs (miRNAs) were profiled by high-throughput sequencing. STAT3 targeting was examined by dual-luciferase reporter assays, and the functional contribution of miR-125b-5p was assessed using exosomes loaded with a miR-125b-5p inhibitory oligonucleotide and negative-control exosomes (NC-Exos). Results: hucMSC-Exos alleviated IMQ-induced psoriasiform dermatitis, as reflected by reduced epidermal hyperplasia and fewer Ki-67-positive keratinocytes. Exosome treatment was associated with decreased phosphorylation of STAT3 and JNK, lower IL-23 and IL-17A expression, decreased Th17-cell frequency, and increased regulatory T cell (Treg)-cell frequency. In vitro, hucMSC-Exos suppressed Th17-cell proliferation while promoting Treg-cell expansion. miR-125b-5p was among the abundant miRNAs detected in hucMSC-Exos, and dual-luciferase reporter assays supported STAT3 as a direct target of miR-125b-5p. Compared with NC-Exos, inhibitor-loaded exosomes (IN-Exos) were less effective at alleviating IMQ-induced psoriasiform dermatitis; this reduced efficacy was accompanied by increased STAT3 and JNK phosphorylation, higher IL-23 and IL-17A expression, a higher Th17-cell frequency, and a lower Treg-cell frequency. Conclusion: hucMSC-Exos attenuated psoriasiform inflammation and were associated with reduced inflammatory signaling, decreased Th17-cell frequency, and increased Treg-cell frequency. Our findings further suggest that exosomal miR-125b-5p contributes, at least in part, to these effects through direct regulation of STAT3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.